The US Food and Drug Administration (FDA) has granted 510(k) clearance to clinical informatics platform ‘IntelliSpace Portal 9.0’ and a range of new radiology applications.

Developed by Royal Philips, the platform is designed for advanced visual analysis and quantification of medical images, as well as advanced applications for longitudinal brain imaging (LoBI), multimodality tumour tracking with qEASL technology, and optimised lung module assessment.

Available outside of the US since November last year, IntelliSpace Portal 9.0 will now offer 70 applications across radiology domains such as neurology, oncology, and cardiology on a single platform.

The platform has the ability to provide an overview of each patient, enabling quantification and quick diagnosis using clinical applications optimised for assessment of the patient over extended time periods.

Philips Healthcare Informatics business leader Yair Briman said: "IntelliSpace Portal shows how we continuously innovate to help clinicians achieve first-time-right diagnoses, track disease development, and improve patient care.

“Our newest clinical informatics innovations can now be used to help streamline care for more and even the most complex patients."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
"Our newest clinical informatics innovations can now be used to help streamline care for more and even the most complex patients."

LoBI is an application developed to analyse brain images and monitor disease progression in patients with neurodegenerative conditions such as stroke, Alzheimer's disease, and multiple sclerosis (MS).

The new multi-modality tumour tracking with qEASL technology enables measurement of tumour volume depending on MRI and CT scans.

The tracking is expected to improve the cancer treatment follow-up standards by providing a visual indication of cell response to therapy.

The lung module assessment is a diagnostic patient imaging tool designed to provide information on quantity and characterisation of lung nodules in a single CT study, or over time during the course of various thoracic studies.

Image: The newest clinical advance on the Intellispace Portal now cleared for US distribution is its longitudinal brain imaging (LoBI). Photo: courtesy of PRNewsfoto/Royal Philips.